Processa Pharmaceuticals Inc (PCSA) - Total Assets
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) holds total assets worth $7.81 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Processa Pharmaceuticals Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Processa Pharmaceuticals Inc - Total Assets Trend (2010–2025)
This chart illustrates how Processa Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Processa Pharmaceuticals Inc net assets for net asset value and shareholders' equity analysis.
Processa Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Processa Pharmaceuticals Inc's total assets of $7.81 Million consist of 72.6% current assets and 27.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.15 Million | 14.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Processa Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PCSA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Processa Pharmaceuticals Inc's current assets represent 72.6% of total assets in 2025, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 70.9% of total assets in 2025, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 14.7% of total assets.
Processa Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Processa Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Processa Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.54 | 1.22 | 22.40 |
| Quick Ratio | 2.54 | 1.22 | 22.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.43 Million | $340.99K | $23.45 Million |
Processa Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Processa Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | 142.0% |
| Total Assets | $7.81 Million |
| Market Capitalization | $5.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Processa Pharmaceuticals Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Processa Pharmaceuticals Inc's assets grew by 142.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Processa Pharmaceuticals Inc (2010–2025)
The table below shows the annual total assets of Processa Pharmaceuticals Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.81 Million | +141.96% |
| 2024-12-31 | $3.23 Million | -44.19% |
| 2023-12-31 | $5.79 Million | -32.87% |
| 2022-12-31 | $8.62 Million | -67.43% |
| 2021-12-31 | $26.46 Million | +4.95% |
| 2020-12-31 | $25.21 Million | +131.68% |
| 2019-12-31 | $10.88 Million | -17.64% |
| 2018-12-31 | $13.21 Million | +343.01% |
| 2017-12-31 | $2.98 Million | +2759.39% |
| 2016-12-31 | $104.32K | 0.00% |
| 2015-12-31 | $104.32K | -95.90% |
| 2014-12-31 | $2.54 Million | -13.48% |
| 2013-12-31 | $2.94 Million | -24.36% |
| 2012-12-31 | $3.88 Million | -26.79% |
| 2011-12-31 | $5.31 Million | +26428.19% |
| 2010-12-31 | $20.00K | -- |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more